-+ 0.00%
-+ 0.00%
-+ 0.00%

Sagimet Biosciences Q3 net loss widens 48% to $19.15 million

PUBT·11/12/2026 12:52:11
Sagimet Biosciences Q3 net loss widens 48% to $19.15 million
  • Sagimet Biosciences’ third-quarter net loss widened 48% year over year to $19.15 million.
  • Research and development expenses rose 68% year over year to $16.34 million in the quarter.
  • Cash, cash equivalents and marketable securities totaled $275.82 million at September 30, 2026.
  • The U.S. AURORA Phase 3 acne trial began dosing in October, with topline denifanstat data expected in the second half of 2027.
  • Current operations are expected to be funded through mid-2029, including the denifanstat Phase 3 data readout and potential NDA submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120730PRIMZONEFULLFEED9875920) on November 12, 2026, and is solely responsible for the information contained therein.